Sienna Biopharmaceuticals (SNNA) IPO Opens Sharply Higher

Today's IPO for Sienna Biopharmaceuticals, Inc. (NASDAQ: SNNA) opened for trading at $19.05 after pricing 4,333,333 shares of common stock at a public offering price of $15.00 per share, before underwriting discounts.

J.P. Morgan and Cowen are acting as joint book-running managers for the proposed offering. BMO Capital Markets is also acting as bookrunner for the proposed offering.

Sienna Biopharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on bringing innovations in biotechnology to the discovery, development and commercialization of first-in-class, targeted, topical products in medical dermatology and aesthetics. Sienna’s objective is to develop an innovative, diversified, multi-asset pipeline of topical therapies that enhance the health, appearance and quality of life of dermatology and aesthetics patients. Sienna is led by a management team with extensive experience in product development and commercialization at several leading dermatology, aesthetics and biotechnology companies.

You May Also Be Interested In

• Nscale targets up to $3B in US IPO as soon as September - Bloomberg
• Singularity Future Technology closes $5M registered direct offering
• Non-Invasive Monitoring Systems files to offer 8.1M shares